ST. HELIER, Jersey (AP) _ NovoCure Ltd. (NVCR) on Thursday reported a loss of $24 million in its second quarter.

The St. Helier, Jersey-based company said it had a loss of 23 cents per share.

The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 14 cents per share.

The oncology drug developer posted revenue of $140.9 million in the period, topping Street forecasts. Five analysts surveyed by Zacks expected $134.9 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVCR at https://www.zacks.com/ap/NVCR

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News